Partager
Actualité

[PUBLICATION] In situ Analytical Quality Control of chemotherapeutic solutions in infusion bags by Raman spectroscopy

  • Recherche,
  • Santé-Sciences-Technologie,
  • Santé-social,
Raman spectroscopy and Chemotherapeutics
Raman spectroscopy and Chemotherapeutics
Date(s)

le 31 mai 2021

Published in Talanta

Collaborative research project led by Dr. Bonnier (EA Nanomédecine, Nanosonde, Université de Tours, France) in which Dr. Tauber participated

In situ Analytical Quality Control of chemotherapeutic solutions in infusion bags by Raman spectroscopy

Abstract

Analytical Quality Control (AQC) in centralised preparation units of oncology centers is a common procedure relying on the identification and quantification of the prepared chemotherapeutic solutions for safe intravenous administration to patients. Although the use of Raman spectroscopy for AQC has gained much interest, in most applications it remains coupled to a flow injection analyser (FIA) requiring withdrawal of the solution for analysis. In addition to current needs for more rapid and cost-effective analysis, the risk of exposure of clinical staff to the toxic molecules during daily handling is a serious concern to address. Raman spectroscopic analysis, for instance by Confocal Raman Microscopy (CRM), could enable direct analysis (non-invasive) for AQC directly in infusion bags. In this study, 3 anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-FU) and gemcitabine (GEM) have been selected to highlight the potential of CRM for withdrawal free analysis. Solutions corresponding to the clinical range of each drug were prepared in 5% glucose and data was collected from infusion bags placed under the Raman microscope. Firstly, 100% discrimination has been obtained by Partial Least Squares Discriminant Analysis (PLS-DA) confirming that the identification of drugs can be performed. Secondly, using Partial Least Squares Regression (PLSR), quantitative analysis was performed with mean % error of predicted concentrations of respectively 3.31%, 5.54% and 8.60% for MTX, 5-FU and GEM. These results are in accordance with the 15% acceptance criteria used for the current clinical standard technique, FIA, and the Limits of Detection for all drugs were determined to be substantially lower than the administered range, thus highlighting the potential of confocal Raman spectroscopy for direct analysis of chemotherapeutic solutions.

Keywords

Analytical quality control; Chemotherapeutics; Confocal Raman micro-spectroscopy; Non-invasive analysis.

Contact :
Dr. Clovis Tauber :